hucMSC-sEVs-Derived 14-3-3ζ Serves as a Bridge between YAP and Autophagy in Diabetic Kidney Disease
As nanoscale membranous vesicles, human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEVs) have attracted extensive attention in the field of tissue regeneration. Under the premise that the mechanisms of hucMSC-sEVs on the treatment of diabetic kidney disease (DKD) have not been revealed clearly, we constructed DKD rat model with success. After tail vein injection, hucMSC-sEVs effectively reduced blood glucose, maintained body weight and improved renal function in DKD rats. Notably, we found that hucMSC-sEVs suppressed YAP expression in renal cortical regions. Further in vitro experiments, we confirmed that the expression of YAP in the nucleus of renal podocytes was increased, and the level of autophagy was inhibited in the high-glucose environment, which could be reversed by intervention with hucMSC-sEVs. We screened out the key protein 14-3-3ζ, which could not only promote YAP cytoplasmic retention instead of entering the nucleus, but also enhance the level of autophagy in the cytoplasm. Ultimately, excessive YAP protein was removed by autophagy, a classic way of protein degradation. In conclusion, our study provides new strategies for the prevention of DKD and proposes the possibility of hucMSC-sEVs becoming a new treatment for DKD in the future.
Top-30
Journals
|
1
|
|
|
Pharmaceutics
1 publication, 5.88%
|
|
|
Drug Discovery Today
1 publication, 5.88%
|
|
|
Cell Communication and Signaling
1 publication, 5.88%
|
|
|
Tissue and Cell
1 publication, 5.88%
|
|
|
bioRxiv
1 publication, 5.88%
|
|
|
Pharmacological Research
1 publication, 5.88%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 5.88%
|
|
|
Neural Regeneration Research
1 publication, 5.88%
|
|
|
European Journal of Pharmacology
1 publication, 5.88%
|
|
|
International Journal of Molecular Sciences
1 publication, 5.88%
|
|
|
Current Stem Cell Research and Therapy
1 publication, 5.88%
|
|
|
Antioxidants and Redox Signaling
1 publication, 5.88%
|
|
|
Therapeutic Advances in Endocrinology and Metabolism
1 publication, 5.88%
|
|
|
World Journal of Stem Cells
1 publication, 5.88%
|
|
|
Molecular Metabolism
1 publication, 5.88%
|
|
|
European Journal of Medical Research
1 publication, 5.88%
|
|
|
Biochemical Pharmacology
1 publication, 5.88%
|
|
|
1
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
Elsevier
7 publications, 41.18%
|
|
|
MDPI
2 publications, 11.76%
|
|
|
Springer Nature
2 publications, 11.76%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 5.88%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 5.88%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 5.88%
|
|
|
Mary Ann Liebert
1 publication, 5.88%
|
|
|
SAGE
1 publication, 5.88%
|
|
|
Baishideng Publishing Group
1 publication, 5.88%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.